Table of contents
- Trial overview
- Who participated
- What was measured
- Phase and status
- What these results mean for patients
Trial overview
NCT05298254 studied GSKVX000000030918 as a targeted immunotherapy for herpes simplex in an interventional trial.[1] The study looked at reactogenicity (short-term reactions after a dose), safety, immune response, and efficacy.[1]
The brief summary says the main goal was to evaluate the reactogenicity and safety of the HSVTI, and for Part II to show whether it could reduce the risk of confirmed HSV-2 recurrent genital herpes episodes.[1]
Who participated
The study included healthy participants aged 18 to 40 years and participants aged 18 to 60 years with recurrent genital herpes.[1] This means the trial was designed for both people without active disease and people who already had repeated genital herpes outbreaks.[1]
The enrollment was 515 participants, which shows that a fairly large number of people took part for an early-stage study.[1]
What was measured
The primary outcomes focused on safety after each dose, including redness, pain, and swelling at the injection site within 7 days.[1] The study also measured fever, fatigue, headache, muscle pain, and joint pain within 7 days after each dose.[1]
Researchers also tracked unsolicited adverse events within 28 days after each dose, as well as major medical events, serious adverse events, and pIMDs from the first dose through 12 months after the last study treatment.[1] pIMDs means newly diagnosed immune-mediated disease or worsening of a pre-existing one, which is a problem linked to the immune system.[1]
For Part I and Part II, the study also checked blood test changes, called haematological and biochemical laboratory abnormalities, after the first and second doses.[1] The key efficacy endpoint was the time to the first confirmed HSV-2 recurrent genital herpes episode.[1]
Phase and status
This was a Phase 1/2 trial, which means it combined early safety testing with an early look at whether the treatment might work.[1] The status of the study is completed.[1]
The study used several treatment groups, including GSKVX000000030918, other study drugs, and a NaCl solution, which is a salt solution used as a comparison treatment in some studies.[1]
What these results mean for patients
This trial is important because it does not only ask whether GSKVX000000030918 can help with recurrent genital herpes, but also whether it can be given safely.[1] Safety questions are especially important in early-phase research, when a treatment is still being tested in people.[1]
For patients, the study shows that researchers are looking at both short-term reactions after each dose and longer-term health changes over many months.[1] It also shows that the trial was focused on a real patient problem: repeated HSV-2 genital herpes episodes.[1]
